<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a rare <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> in children </plain></SENT>
<SENT sid="1" pm="."><plain>It was performed FISH analysis in 19 pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients to investigate deletions involving the PPARgamma and TP53 genes </plain></SENT>
<SENT sid="2" pm="."><plain>Significant losses in the PPARgamma gene and deletions in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene TP53 were observed in 17 and 18 cases, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Using quantitative RT-PCR, it was detected PPARgamma transcript downexpression in a subset of these cases </plain></SENT>
<SENT sid="4" pm="."><plain>G-banding analysis revealed 17p deletions in a small number of these cases </plain></SENT>
<SENT sid="5" pm="."><plain>One <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> therapy-related patient had neither a loss of PPARgamma nor TP53 </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest that the PPARgamma and TP53 genes may be candidates for molecular markers in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and that these potentially recurrent deletions could contribute to the identification of therapeutic approaches in primary pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>